Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
11.98
-0.19 (-1.56%)
Feb 13, 2026, 3:04 PM CST
Market Cap19.16B +4.1%
Revenue (ttm)2.40B -22.5%
Net Income49.24M -59.8%
EPS0.03 -59.8%
Shares Out1.60B
PE Ratio389.08
Forward PE73.72
Dividend0.03 (0.25%)
Ex-Dividend DateJan 9, 2026
Volume26,686,586
Average Volume62,895,479
Open12.21
Previous Close12.17
Day's Range11.97 - 12.23
52-Week Range9.70 - 14.65
Beta0.57
RSI44.51
Earnings DateMar 28, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The... [Read more]

Sector Healthcare
Founded 2001
Employees 2,388
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.

Financial Statements